FBXO11-loss Is a Novel Determinant of PARP Inhibitor Resistance in Small-Cell Lung Cancer

Lynparza (olaparib) - Merck (MSD), AstraZeneca

Talzenna (talazoparib) - Pfizer

J. Xiong1; L. Song1; M. Aparnathi1; T. Yu1; S. Ul-Haq2; J. St-Germain1; B. Raught1; T. Ketela1; V. Philip1; B.H. Lok1

Jul 31, 2026